Risk factors for skeletal-related events in patients with stage IV lung adenocarcinoma and bone metastases receiving denosumab: a retrospective cohort analysis
Supportive Care in Cancer · 2026-01 · 34 (1)
DOI: 10.1007/s00520-025-10296-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Supportive Care in Cancer, online erschienen am 06.01.2026. Verfasst von Hui Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Xuanhan County People's Hospital, 753 Jiefang Middle Road, East Township, Xuanhan County, Sichuan, China. Hauptthemen laut MEDLINE: Denosumab, Lung Neoplasms, Bone Neoplasms, Adenocarcinoma of Lung. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Xuanhan County Science and Technology Plan Project.
Abstract (Originalsprache)
Purpose
This study aimed to identify independent risk factors for skeletal-related events(SREs) during denosumab treatment in patients with bone-metastatic stage IV lung adenocarcinoma by integrating multidimensional clinical parameters, thereby providing an evidence-based foundation for risk stratification and targeted management.
Methods
In this retrospective cohort study, patients with stage IV lung adenocarcinoma and radiologically confirmed bone metastases diagnosed at Xuanhan County People's Hospital between July 2021 and December 2023 were enrolled. All patients received standardized denosumab therapy (120 mg subcutaneously every 4 weeks ± 7 days). Baseline demographic, laboratory, and treatment response data were extracted from the electronic medical record system. Univariate analyses were used to screen candidate variables, followed by multivariate logistic regression to identify independent predictors. Model fit was assessed using the Hosmer–Lemeshow test.
Results
A total of 111 patients were included (median age, 65.5 years; 50.45% male). During follow-up, 27 patients (24.3%) experienced SREs. Multivariate analysis identified a prior history of bisphosphonate use as an independent protective factor against SREs (odds ratio [OR], 0.191; 95% confidence interval [CI], 0.049–0.741 P = 0.017), while Pretreatment hypocalcemia and smoking were both significantly associated with increased risk.
Conclusions
This study is the first to demonstrate in a county-level hospital cohort that a history of bisphosphonate use serves as an independent protective factor against SREs during denosumab treatment, while Pretreatment hypocalcemia and smoking history significantly increase SREs risk. These findings provide critical evidence for individualized management of stage IV lung adenocarcinoma patients with bone metastases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Xuanhan County People's Hospital, 753 Jiefang Middle Road, East Township, Xuanhan County, Sichuan, China.
- Xuanhan County People's Hospital, 753 Jiefang Middle Road, East Township, Xuanhan County, Sichuan, China. 41474646@qq.com.
Förderung
- Xuanhan County Science and Technology Plan Project
Zitieren
APA
Zhang, H., Wen, D., Liao, Z., Tan, X., Wang, H., Xiang, J., & Yan, B. (2026). Risk factors for skeletal-related events in patients with stage IV lung adenocarcinoma and bone metastases receiving denosumab: a retrospective cohort analysis. Supportive Care in Cancer, 34(1). https://doi.org/10.1007/s00520-025-10296-0
Vancouver
Zhang H, Wen D, Liao Z, Tan X, Wang H, Xiang J, et al. Risk factors for skeletal-related events in patients with stage IV lung adenocarcinoma and bone metastases receiving denosumab: a retrospective cohort analysis. Supportive Care in Cancer. 2026;34(1). doi:10.1007/s00520-025-10296-0
BibTeX
@article{Zhang2026,
author = {Zhang, Hui and Wen, Daochen and Liao, Zhou and Tan, Xiaoyong and Wang, Hao and Xiang, Jianxia and Yan, Bing},
title = {Risk factors for skeletal-related events in patients with stage IV lung adenocarcinoma and bone metastases receiving denosumab: a retrospective cohort analysis},
journal = {Supportive Care in Cancer},
year = {2026},
volume = {34},
number = {1},
doi = {10.1007/s00520-025-10296-0}
}
EUVIMED